MOREPENLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Morepen Laboratories board has approved transfer of 1,62,000 equity shares of its subsidiary Morepen Medipath Limited (MML) to Mr. Anubhav Suri, Head of Medical Device Business. As a result, the company's stake in MML has reduced from 60% to 51%. MML continues to remain a subsidiary and will be consolidated in the company's financial statements. Mr. Anubhav Suri's shareholding in MML increases from 0.10% to 9.10%. The company states this is to recognize his 15 years of leadership in growing the medical devices business and to align his interests with long-term growth objectives of MML.
Morepen Laboratories retains control of MML despite reducing stake, so consolidation continues. This looks like an employee incentivization move to retain key management in the growing medical devices business. No immediate material impact on Morepen Laboratories standalone financials expected.